Modus Therapeutics is focused on developing sevuparin, a proprietary polysaccharide, as a potential therapeutic solution for severe medical conditions characterized by high unmet medical needs, particularly sepsis and systemic inflammation. Sepsis, a critical condition that can lead to septic shock and multi-organ failure, poses significant treatment challenges and is associated with high mortality rates in intensive care settings. The company highlights the economic burden of sepsis treatment, which has seen rising costs in both the US and UK healthcare systems. Currently, there are no specific pharmaceutical treatments available for sepsis, and the standard care involves a combination of aggressive supportive measures and antibiotics.

The preclinical research conducted by Modus Therapeutics indicates that sevuparin may offer protective effects on the vascular system, particularly in the lungs, by modulating the actions of white blood cells involved in the inflammatory response. This potential has been demonstrated in both cellular studies and mouse models, as well as in clinical trials involving healthy volunteers subjected to induced systemic inflammation. The company aims to address the critical gap in effective treatments for sepsis and other severe inflammatory disorders, including severe malaria and anemia related to chronic inflammation, thereby improving patient outcomes in these high-risk populations.

Sweden

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.

Modus Therapeutics

Company Details